Sign up to save your podcasts
Or
Share EXUMA Biotech Inks $19M Series B Round
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
EXUMA Biotech Inks $19M Series B Round
EXUMA Biotech Inks $19M Series B Round Back to HomeWEST PALM BEACH, FL, EXUMA Biotech announced a $19M Series B round of financing.
EXUMA Biotech Corp. (formerly F1 Oncology), a clinical-stage biotechnology company discovering and developing CAR-T therapies for solid and liquid tumors, today announced a $19M Series B round of financing that includes new investments by MSD Partners and F1 BioVentures, as well as conversion of notes held by individual investors.
EXUMA Biotech Corp. and its affiliates will be utilizing these proceeds to advance new logic gated CAR-T therapies for solid tumor malignancies as well as for further development and partnering of its rapid point-of-care (or "rPOC"), same-day CAR-T platform technology.
Scott Segal is a Managing Director at MSD Partners ("MSD"), where he invests across a range of sectors, in both debt and structured equity.
About EXUMA Biotech CorpEXUMA Biotech Corp is a private Delaware corporation formed in November 2015 with operations in West Palm Beach, Florida and international affiliates in the Cayman Islands and Shanghai, China. | To read full story, visit https://startuparound.com/read/1584117007.2416275/EXUMA-Biotech-Inks-$19M-Series-B-Round?ref=audio_experience
View all episodes
By Startup AroundEXUMA Biotech Inks $19M Series B Round Back to HomeWEST PALM BEACH, FL, EXUMA Biotech announced a $19M Series B round of financing.
EXUMA Biotech Corp. (formerly F1 Oncology), a clinical-stage biotechnology company discovering and developing CAR-T therapies for solid and liquid tumors, today announced a $19M Series B round of financing that includes new investments by MSD Partners and F1 BioVentures, as well as conversion of notes held by individual investors.
EXUMA Biotech Corp. and its affiliates will be utilizing these proceeds to advance new logic gated CAR-T therapies for solid tumor malignancies as well as for further development and partnering of its rapid point-of-care (or "rPOC"), same-day CAR-T platform technology.
Scott Segal is a Managing Director at MSD Partners ("MSD"), where he invests across a range of sectors, in both debt and structured equity.
About EXUMA Biotech CorpEXUMA Biotech Corp is a private Delaware corporation formed in November 2015 with operations in West Palm Beach, Florida and international affiliates in the Cayman Islands and Shanghai, China. | To read full story, visit https://startuparound.com/read/1584117007.2416275/EXUMA-Biotech-Inks-$19M-Series-B-Round?ref=audio_experience